SCHEMBL26170010

SCHEMBL26170010

Cn1ncc2cc(B(O)O)ccc2c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
RAF1 P04049 1/20 0.36
BRAF P15056 1/20 0.36
CHEK1 O14757 1/20 0.34
FLT3 P36888 1/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ERCC1 P07992 1/20 0.32
ERCC4 Q92889 1/20 0.32
KAT2B Q92831 2/20 0.32
BRD9 Q9H8M2 2/20 0.32
ALDH1A1 P00352 2/20 0.31
LRRK2 Q5S007 1/20 0.31
POLB P06746 1/20 0.31
ENPP2 Q13822 1/20 0.31
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7600934 0.77 BRD4 (0.41) RAF1BRAFCHEK1FLT3NPC1
SCHEMBL21172 0.77 TRPA1 (0.42) CA1CA2NPC1RAB9AALDH1A1
SCHEMBL29722623 0.77 TRPA1 (0.42) CA1CA2NPC1RAB9AALDH1A1
SCHEMBL11607246 0.76 NPC1 (0.43) NPC1RAB9ASMN1; SMN2KAT2BBRD9
SCHEMBL16013953 0.76 CHEK1 (0.44) RAF1BRAFCHEK1FLT3NPC1
SCHEMBL16013889 0.76 KMT2A (0.43) RAF1BRAFCHEK1FLT3NPC1
SCHEMBL2627964 0.74 RAB9A (0.43) CA1CA2NPC1RAB9ASMN1; SMN2
SCHEMBL2627966 0.74 CA2 (0.39) CA1CA2IDO1TDO2BRD9
SCHEMBL25151028 0.74 GRM1 (0.39)
SCHEMBL29953317 0.73 NOTUM (0.44) CA1CA2ERCC1ERCC4ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159496-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159496-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 CA1 4082/4885CA2 4843/4885RAF1 3887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.